What is claimed:

1. Use of a non-aqueous pharmaceutical composition comprising dantrolene, or a pharmaceutically acceptable salt thereof, or a mixture thereof, and a pharmaceutically acceptable carrier comprising PEG 400 or propylene glycol, or a mixture thereof, for treating a disorder;
   wherein the disorder is malignant hyperthermia, chronic spasticity, exertional heat stroke, cardiac arrhythmias, tachycardis, atrial fibrillation, cardiac arrest, heart failure, detrusor overactivity, overactive bladder, neuroleptic malignant syndrome, Alzheimer's disease, Huntington's disease, ischemia-reperfusion injury, neuronal reperfusion injury, hyperthermia associated with drug abuse, hyperthermia associated with drug overdose; wherein the pharmaceutical composition has an effective pH of 4 to 9; wherein the pharmaceutical composition is to be administered intramuscularly or subcutaneously.

2. The use of claim 1, wherein the pharmaceutical composition has an effective pH of 5 to 8.

3. The use of any one of the preceding claims wherein the pharmaceutical composition comprises dantrolene.

4. The use of any one of the preceding claims wherein the pharmaceutical composition comprises dantrolene sodium.

5. The use of any one of the preceding claims wherein the pharmaceutical composition comprises dantrolene and dantrolene sodium.

6. The use of any one of the preceding claims, wherein the carrier comprises propylene glycol.

7. The use of any one of the preceding claims, wherein the carrier comprises PEG 400.

8. The use of any one of the preceding claims wherein the pharmaceutical composition further comprises an additional pharmaceutically acceptable excipient.